INDIVIDUALIZATION OF HIGH-DOSE METHOTREXATE POSOLOGY BY DETERMINATION OF PLASMA-CONCENTRATIONS AND ITS ROLE IN THE TREATMENT OF OSTEOGENIC-SARCOMA

被引：0
|
作者：
DELEPINE, N
DESBOIS, JC
DELEPINE, G
CORNILLE, H
ASTIER, A
ALKALLAF, S
机构：
[1] CLIN PRE GENTIL,UNITE ONCOL ORTHOPED,F-93000 ROSNY BOIS,FRANCE
[2] HOP HENRI MONDOR,SERV TOXICOL,F-94000 CRETEIL,FRANCE
来源：
BULLETIN DU CANCER | 1989年 / 76卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：913 / 918
页数：6
相关论文
共 50 条
  • [41] TREATMENT OF SOLID TUMORS WITH HIGH-DOSE METHOTREXATE ITS RISKS
    BOUFFET, E
    PHILIP, T
    POUYAU, G
    BIGOT, P
    BRUNATMENTIGNY, M
    PEDIATRIE, 1981, 36 (04): : 263 - 269
  • [42] DETERMINATION OF METHOTREXATE PLASMA-LEVELS IN HIGH-DOSE METHOTREXATE WITH CITROVORUM FACTOR RESCUE PROGRAM
    ZYLBERKATZ, E
    SULKES, A
    LEVY, M
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1978, 14 (09): : 1004 - 1004
  • [43] SERUM DISTRIBUTION OF 5-METHYLTETRAHYDROFOLATE (5-MTHFA) FOLLOWING HIGH-DOSE METHOTREXATE-LEUCOVORIN (HDMTX-LV) RESCUE REGIMEN IN OSTEOGENIC-SARCOMA
    MEHTA, BM
    ROSEN, G
    HUTCHISON, DJ
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 127 - 127
  • [44] ADJUVANT HIGH DOSE METHOTREXATE AND CITROVORUM RESCUE(HDMC) FOLLOWING PRIMARY TREATMENT OF OSTEOGENIC SARCOMA
    JAFFE, N
    TRAGGIS, D
    ANDONIAN, S
    CHAN, D
    SALLAN, S
    KIM, T
    FREI, E
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1974, 15 (MAR): : 132 - 132
  • [45] TOXICITY OF HIGH-DOSE METHOTREXATE (NSC-740) AND CITROVORUM FACTOR (NSC-3590) IN OSTEOGENIC SARCOMA
    JAFFE, N
    TRAGGIS, D
    CANCER CHEMOTHERAPY REPORTS PART 3 PROGRAM INFORMATION-SUPPLEMENT, 1975, 6 (01): : 31 - 36
  • [46] FAVORABLE RESPONSE OF METASTATIC OSTEOGENIC SARCOMA TO PULSE HIGH-DOSE METHOTREXATE WITH CITROVORUM RESCUE AND RADIATION-THERAPY
    JAFFE, N
    FARBER, S
    TRAGGIS, D
    GEISER, C
    KIM, BS
    DAS, L
    FRAUENBERGER, G
    DJERASSI, I
    CASSADY, JR
    CANCER, 1973, 31 (06) : 1367 - 1373
  • [47] Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies
    Xu, Wei-qun
    Zhang, Ling-yan
    Chen, Xue-ying
    Pan, Bin-hua
    Mao, Jun-qing
    Song, Hua
    Li, Jing-yuang
    Tang, Yong-min
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (01) : 79 - 86
  • [48] Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies
    Wei-qun Xu
    Ling-yan Zhang
    Xue-ying Chen
    Bin-hua Pan
    Jun-qing Mao
    Hua Song
    Jing-yuang Li
    Yong-min Tang
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 79 - 86
  • [49] Correlation of cerebrospinal fluid β-glucuronidase activity with plasma methotrexate concentrations in leukemic children receiving high-dose methotrexate
    Vlacha, V
    Eliopoulou, M
    Haidas, S
    Beratis, NG
    PEDIATRIC BLOOD & CANCER, 2004, 42 (04) : 350 - 356
  • [50] Plasma concentration monitoring during high-dose methotrexate treatment in childhood leukemia
    Ayna, T. K.
    Ciftci, H. S.
    Aydogan, G.
    Sen, H. S., I
    Akici, F.
    Tucu, D.
    Akcay, A.
    Salciolu, Z.
    Gurtekin, M.
    THERAPEUTIC DRUG MONITORING, 2011, 33 (04) : 549 - 549
12345